Fridays vs NexLife (2026): prices, structure, verdict

On tirzepatide, NexLife↗ is cheaper: $215 versus $359 a month all-in — a $144 monthly gap, $1,728 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, NexLife is cheaper: $165 versus $175 a month all-in — a $10 monthly gap, $120 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fridays: the record, condensed

On tirzepatide, the number that matters at Fridays is $359 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #13 of 17 verified programs, with the floor $144/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $90 a month. A year at this figure: $4,308 monthly-billed.

Fridays’s semaglutide program bills $175 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #7 of 20 in the verified semaglutide index — $42/month above the floor (Oak Longevity, $133) — and sits $174 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,100.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

NexLife: the record, condensed

On tirzepatide, the number that matters at NexLife is $215 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $215 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Treat every rung as what it is — a prepayment, not a monthly price. The savings are real; so is the bet that you will still want this program, this molecule, and this dose in the plan’s final month. Written refund terms before prepaying, always.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for tirzepatide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #1 of 17 verified programs, holding the floor outright; the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $234 a month. A year at this figure: $2,580 monthly-billed ($2,232 prepaid).

On semaglutide, the number that matters at NexLife is $165 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic semaglutide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #5 of 20 in the verified semaglutide index — $32/month above the floor (Oak Longevity, $133) — and sits $184 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,980, or $1,740 on the prepaid path.

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: NexLife at $215, Fridays at $359 — a $144 monthly spread that compounds to $1,728 over a maintenance year and $3,456 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $144 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $165 (NexLife) against $175 (Fridays). $10 a month sounds survivable; $120 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $10 gap is exactly what it appears to be.

A way to feel the $144 monthly gap: over a year it funds 8.0 extra months at NexLife’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $3,456, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Fridays $359/mo month-to-month against NexLife $186/mo on the labeled 12-month plan ($2,232 upfront; $215 month-to-month). The order holds: NexLife leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Fridays $1,077 monthly; NexLife $645 monthly (or $585 prepaid) — best path favors NexLife by $492. 6 months: Fridays $2,154 monthly; NexLife $1,290 monthly (or $1,140 prepaid) — best path favors NexLife by $1,014. 12 months: Fridays $4,308 monthly; NexLife $2,580 monthly (or $2,232 prepaid) — best path favors NexLife by $2,076. 24 months: Fridays $8,616 monthly; NexLife $5,160 monthly (or $4,464 prepaid) — best path favors NexLife by $4,152.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Fridays $525 vs NexLife $447 (prepaid) — $78 to NexLife. 6 mo: Fridays $1,050 vs NexLife $882 (prepaid) — $168 to NexLife. 12 mo: Fridays $2,100 vs NexLife $1,740 (prepaid) — $360 to NexLife. 24 mo: Fridays $4,200 vs NexLife $3,480 (prepaid) — $720 to NexLife.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Fridays publishes “not published”; NexLife publishes “50 states published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NexLife names its network (6 named partner pharmacies); Fridays does not, which shifts the burden of verification onto your intake questions.

Exit terms: Fridays — annual plan for lowest rate; not published. NexLife — none on monthly; cancel any time on monthly.

Evidence: Fridays third-party reported (captured 2026-08-05); NexLife source-verified (2026-08-10).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #13 and #1 of 17: between them lie 11 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #7 and #5 of 20: between them lie 1 other program, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Fridays and NexLife

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fridays: not published; NexLife: cancel any time on monthly) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings